Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies.
nasal cavity
paranasal sinus
pencil beam proton therapy
radiotherapy
reirradiation
toxicity
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 01 2020
01 01 2020
Historique:
received:
18
12
2019
revised:
12
01
2020
accepted:
21
01
2020
pubmed:
26
2
2020
medline:
22
12
2020
entrez:
26
2
2020
Statut:
ppublish
Résumé
Proton therapy (PT) improves outcomes in patients with nasal cavity (NC) and paranasal sinus (PNS) cancers. Herein, the authors have reported to their knowledge the largest series to date using intensity-modulated proton therapy (IMPT) in the treatment of these patients. Between 2013 and 2018, a total of 86 consecutive patients (68 of whom were radiation-naive and 18 of whom were reirradiated) received PT to median doses of 70 grays and 67 grays relative biological effectiveness, respectively. Approximately 53% received IMPT. The median follow-up was 23.4 months (range, 1.7-69.3 months) for all patients and 28.1 months (range, 2.3-69.3 months) for surviving patients. The 2-year local control (LC), distant control, disease-free survival, and overall survival rates were 83%, 84%, 74%, and 81%, respectively, for radiation-naive patients and 77%, 80%, 54%, and 66%, respectively for reirradiated patients. Among radiation-naive patients, when compared with 3-dimensional conformal proton technique, IMPT significantly improved LC (91% vs 72%; P < .01) and independently predicted LC (hazard ratio, 0.14; P = .01). Sixteen radiation-naive patients (24%) experienced acute grade 3 toxicities; 4 (6%) experienced late grade 3 toxicities (osteoradionecrosis, vision loss, soft-tissue necrosis, and soft tissue fibrosis) (grading was performed according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 5.0]). Slightly inferior LC was noted for patients undergoing reirradiation with higher complications: 11% experienced late grade 3 toxicities (facial pain and brain necrosis). Patients treated with reirradiation had more grade 1 to 2 radionecrosis than radiation-naive patients (brain: 33% vs 7% and osteoradionecrosis: 17% vs 3%). PT achieved remarkable LC for patients with nasal cavity and paranasal sinus cancers with lower grade 3 toxicities relative to historical reports. IMPT has the potential to improve the therapeutic ratio in these malignancies and is worthy of further investigation.
Sections du résumé
BACKGROUND
Proton therapy (PT) improves outcomes in patients with nasal cavity (NC) and paranasal sinus (PNS) cancers. Herein, the authors have reported to their knowledge the largest series to date using intensity-modulated proton therapy (IMPT) in the treatment of these patients.
METHODS
Between 2013 and 2018, a total of 86 consecutive patients (68 of whom were radiation-naive and 18 of whom were reirradiated) received PT to median doses of 70 grays and 67 grays relative biological effectiveness, respectively. Approximately 53% received IMPT.
RESULTS
The median follow-up was 23.4 months (range, 1.7-69.3 months) for all patients and 28.1 months (range, 2.3-69.3 months) for surviving patients. The 2-year local control (LC), distant control, disease-free survival, and overall survival rates were 83%, 84%, 74%, and 81%, respectively, for radiation-naive patients and 77%, 80%, 54%, and 66%, respectively for reirradiated patients. Among radiation-naive patients, when compared with 3-dimensional conformal proton technique, IMPT significantly improved LC (91% vs 72%; P < .01) and independently predicted LC (hazard ratio, 0.14; P = .01). Sixteen radiation-naive patients (24%) experienced acute grade 3 toxicities; 4 (6%) experienced late grade 3 toxicities (osteoradionecrosis, vision loss, soft-tissue necrosis, and soft tissue fibrosis) (grading was performed according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 5.0]). Slightly inferior LC was noted for patients undergoing reirradiation with higher complications: 11% experienced late grade 3 toxicities (facial pain and brain necrosis). Patients treated with reirradiation had more grade 1 to 2 radionecrosis than radiation-naive patients (brain: 33% vs 7% and osteoradionecrosis: 17% vs 3%).
CONCLUSIONS
PT achieved remarkable LC for patients with nasal cavity and paranasal sinus cancers with lower grade 3 toxicities relative to historical reports. IMPT has the potential to improve the therapeutic ratio in these malignancies and is worthy of further investigation.
Identifiants
pubmed: 32097507
doi: 10.1002/cncr.32776
pmc: PMC7304541
mid: NIHMS1556311
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1905-1916Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2020 American Cancer Society.
Références
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):691-702
pubmed: 17161557
J Clin Oncol. 2009 Aug 1;27(22):3684-90
pubmed: 19564532
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):763-9
pubmed: 18395361
Head Neck. 2008 Jul;30(7):925-32
pubmed: 18302261
Laryngoscope. 2009 May;119(5):899-906
pubmed: 19358246
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):62-69
pubmed: 27084629
Radiat Oncol. 2016 Feb 27;11:32
pubmed: 26922239
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):151-7
pubmed: 17189068
Int J Clin Oncol. 2015 Jun;20(3):447-54
pubmed: 25135461
Head Neck. 2008 Feb;30(2):222-9
pubmed: 17902164
Tumori. 2008 May-Jun;94(3):320-6
pubmed: 18705398
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):377-385
pubmed: 27084655
Head Neck. 2017 Sep;39(9):1819-1824
pubmed: 28561906
Radiother Oncol. 2016 Feb;118(2):286-92
pubmed: 26867969
Head Neck. 2011 Sep;33(9):1352-65
pubmed: 20737500
Head Neck. 2019 Aug;41(8):2741-2747
pubmed: 30933393
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):243-51
pubmed: 22019239
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1473-8
pubmed: 20961697
Cancer. 2003 Sep 15;98(6):1179-87
pubmed: 12973841
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1042-50
pubmed: 17570610
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):368-376
pubmed: 27084654
PLoS One. 2016 Mar 31;11(3):e0152477
pubmed: 27030987
Head Neck. 2009 Oct;31(10):1297-308
pubmed: 19536762
Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):141-7
pubmed: 17459609
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):424-32
pubmed: 18755554
Radiother Oncol. 2006 Dec;81(3):243-9
pubmed: 17050017
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):704-11
pubmed: 22099036
Head Neck. 2012 Jun;34(6):877-85
pubmed: 22127982
Head Neck. 2016 Apr;38 Suppl 1:E2112-7
pubmed: 26854649
Lancet Oncol. 2014 Aug;15(9):1027-38
pubmed: 24980873
Head Neck. 2017 Mar;39(3):407-418
pubmed: 28032679
Cancer. 2001 Dec 15;92(12):3012-29
pubmed: 11753979
Jpn J Clin Oncol. 2012 Aug;42(8):691-6
pubmed: 22761254
Radiother Oncol. 2017 Mar;122(3):368-372
pubmed: 28062086
Head Neck. 2005 Jul;27(7):575-84
pubmed: 15825201
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):291-8
pubmed: 21167652
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):401-6
pubmed: 18164845
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):998-1004
pubmed: 20338694
Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1343-51
pubmed: 18963535
Am J Clin Oncol. 2015 Jun;38(3):311-4
pubmed: 23822985